2 enrolling by invitation. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Enrolling by invitation 2 |
Follow Metabolic Syndrome: new trials by email Literature Review of Metabolic Syndrome trials Research Report on Metabolic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor Empagliflozin (oral), Matching placebo - Metabolic Syndrome | Phase 3 | Enrolling by invitation | The University of Hong Kong | 160 | 2025-08-13 | 2025-08-24 |
| Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment., A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC - Metabolic Syndrome, Cardiovascular Disease (CKD) | Phase 3 | Enrolling by invitation | Guangdong Provincial Hospital of Traditional Chinese Medicine | 530 | 2025-04-24 | 2025-06-13 |
Cardiovascular Diseases (1) · Cerebrovascular Disorders (1)
Glucose Metabolism Disorders (2) · Hyperinsulinism (2) · Insulin Resistance (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Nervous System Diseases (1) · Vascular Diseases (1)
Color (1) · Dosage Forms (1) · Taste (1) · Weights and Measures (1) · empagliflozin (1)
Guangdong Provincial Hospital of Traditional Chinese Medicine (1) · The University of Hong Kong (1)
China (1) · Hong Kong (1)